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Introduction: The 6-min walk test (6MWT) has prognostic value in various pulmonary
disorders including idiopathic pulmonary fibrosis (IPF). We determined the individual
prognostic accuracy of distance walked and oxygen saturation during the 6MWT in
patients with IPF. We defined a new composite index, the distance-saturation
product (DSP), which is the product of distance walked and lowest oxygen saturation
during the 6-min walk test. We compared the performance of the DSP to the
individual 6MWT parameters in predicting mortality.
Methods: We evaluated pulmonary function tests, 6-min walk parameters and the
DSP between survivors and non-survivors. The ability of each measure to
discriminate outcomes was determined by receiver operator curves.
Results: 81 patients (48 survivors, 33 non-survivors) were included. Pulmonary
function tests were similar and did not correlate with survival. Desaturation was
greater (89.4% versus 83.7%, Po0:001) and distance walked was lower (406.9 versus
181.3m, P ¼ 0:005) in non-survivors. The DSP was significantly lower among non-
survivors (364.8 versus 153.5m%, Po0:001) and predicted mortality more accurately
than either individual 6MWT component (P ¼ 0:035 versus desaturation, P ¼ 0:040
versus distance). A DSPo200m% was associated with a seven-fold greater risk of 12-
month mortality and an 18.0% shorter median survival compared with a DSP4200m%
(Po0:001).
Discussion: Each component of the 6-min walk independently predicted mortality in
IPF with greater accuracy than spirometry. However, a composite of bothed by Elsevier Ltd.
not to be construed as official or as reflecting the policies of either the Department of the Army
thors have no potential financial conflicts of interest.
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Distance-saturation product in IPF 1735parameters, the DSP, provides slightly greater accuracy and represents a novel
measure for assessing survival in patients with IPF.
Published by Elsevier Ltd.Introduction
Idiopathic pulmonary fibrosis (IPF) is a generally
progressive and fatal disease. Lung transplantation
is the only intervention that has been reliably
shown to improve outcomes in this population, but
this is only available to a limited number of eligible
patients. Despite this frustration, clinicians must
counsel patients as to the generally poor prognosis
of their condition, the lack of proven effective
therapies and the possibility of enrollment in
clinical trials. To this end, several variables have
been evaluated as predictors of outcomes. Many of
these simple static tools, such as spirometry and
diffusion capacity for carbon monoxide (DLCO),
perform poorly at forecasting short- and inter-
mediate-term survival.1–10 Because of the limita-
tions with these measures, researchers have
created more complex scoring systems utilizing
physiologic, radiographic and histopathologic char-
acteristics.1–6,11–16 Although these indices afford
better accuracy at estimating survival, they may be
cumbersome to perform in clinical practice and
have not been validated outside of major IPF
referral centers.
In a number of pulmonary conditions, dynamic
assessments of exercise performance project survi-
val with greater precision than static measures of
lung function. In IPF specifically, results from
cardiopulmonary exercise testing (CPET) have
been shown to predict survival.17 CPET requires
specialized equipment, is time consuming and
may have poor reproducibility in patients with
fibrotic idiopathic interstitial pneumonia.18 The
6-min walk test (6MWT), however, is a simpler
and more reproducible tool for assessing exercise
performance.
Recent studies have demonstrated the utility of
the 6MWT in patients with IPF. Data obtained from
the 6MWT not only helps determine the need for
supplemental oxygen but has also been shown to
independently correlate with survival.18–20 Lama
and associates have shown that desaturation to
o89% during the 6MWT is associated with greater
mortality and is more predictive of outcomes than
distance walked in patients with IPF.19 Conversely,
Eaton and associates have shown that the distance
walked during the 6MWT is highly reproducible but
the SpO2 shows more variability and may not be areliable predictor of outcomes in patients with
fibrotic lung disease.18 Similarly, distance walked
during the 6MWT has been shown to discriminate
survivors from non-survivors in other chronic lung
diseases, such as chronic obstructive pulmonary
disease and pulmonary arterial hypertension.17,21–23
We sought to assess whether the distance walked
or the degree of desaturation during the 6MWTwas
a more reliable predictor of outcomes in patients
with IPF. We hypothesized that the incorporation of
both parameters into one composite variable would
provide a more accurate assessment of outcomes in
this patient population. Therefore, we defined a
new index, the distance-saturation product (DSP)
which integrates both the distanced walked and
lowest oxygen saturation (SpO2) and is the product
of these two measurements. We theorized that the
DSP would capture the global physiologic derange-
ments in IPF, including the impact of co-morbid
conditions, and thereby serve as a reliable marker
of intermediate-term survival in this disease.Methods
Subjects
We conducted a retrospective review of all patients
with IPF seen at our clinic between January 1998
and January 2004. Our clinic (Inova Fairfax Hospi-
tal) is both an IPF and lung transplant referral
center. All subjects met accepted diagnostic
criteria for IPF per the American Thoracic Society
(ATS)/European Respiratory Society guidelines and
had histopathologic evidence of usual interstitial
pneumonia.24 Although these guidelines were not
published until 2000, we verified that all included
subjects fulfilled the criteria outlined in these
guidelines. Subjects had to have contemporaneous
(77 days) pulmonary function tests (PFTs) with the
6MWT. We excluded from analysis patients under-
going lung transplant during the follow-up period as
this would alter the natural history of the disease.Measurements
We recorded demographic data, PFT results, resting
room air SpO2, and the outcome of the 6MWT. PFT
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capacity (FVC), forced expiratory volume in 1 s
(FEV1), total lung capacity (TLC), and DLCO. The
prediction equations of Knudson et al.25 were
employed and corrections were made for race.
The 6MWT was conducted in accordance with the
recommendations of the ATS.26 Some 6MWTs in-
cluded in this analysis were performed prior to the
latest ATS guidelines. Each study was reviewed to
ensure that data obtained conformed to the
current ATS standards.
We excluded 6MWTs performed on supplemental
oxygen and all included 6MWTs were performed on
room air. This served to standardize the data and
eliminate supplemental oxygen as a confounding
factor in the determination of the prognostic utility
of desaturation and the SpO2 nadir during the
6MWT. All patients with IPF seen during the study
period were included and, therefore, the final
cohort included both patients with and without
supplemental oxygen requirements. When applic-
able, supplemental oxygen was withdrawn and the
SpO2 was measured after sitting quietly at rest for
5min. Patients unable to maintain a resting
SpO2X88% on room air were excluded from the
study. Patients able to maintain a resting, room air
SpO2X88% were instructed to walk at his/her own
pace for a maximum of 6min. The test was
terminated if the SpO2 fell below 80%. Total
distance walked during the 6MWT was measured,
as was the SpO2 during each minute of the test. As
noted earlier, we defined the DSP as the product of
the final distance walked in meters and the lowest
room air SpO2. For example, a patient walking a
total of 200m who’s SpO2 fell to 90% would have a
DSP of 180m% (e.g., 200 0.90).Endpoints
Our primary endpoint was 12-month survival after
the initial 6MWT. We confirmed mortality by
reviewing records in the Social Security Death
Index. Actuarial survival represented a secondary
endpoint. We explored whether any of the vari-
ables noted earlier (e.g., demographics, PFTS,
6MWT distance, SpO2, and DSP) correlated with
these endpoints.Statistical analysis
We initially compared continuous variables with the
Student’s t-test and analyzed categorical variables
with the Fisher’s exact test. To evaluate the
predictive power of the various inputs we mea-
sured, we constructed receiver operating curves(ROCs) for these different variables as a function of
their ability to predict 12-month mortality. ROC
curves were compared via comparison of the area
under the curve (AUC). After identifying the DSP
value that generated the highest AUC, we then
constructed actuarial survival curves comparing
those with DSPs above this threshold to those with
DSPs falling below this breakpoint. This survival
analysis was completed according to the methods
of Kaplan and Meir. We further determined the
sensitivity and specificity at predicting mortality of
each measured variable with standard 2 2 tables.
All tests were two tailed and P-values of less than
0.05 were assumed to represent statistical signifi-
cance. All analyzes were competed using the SPSS
12.0 software package (SPSS, Inc., Chicago, IL,
USA).Results
During the study period, 106 patients with IPF were
evaluated at our clinic. Nineteen individuals under-
went lung transplantation and were excluded from
further analysis. Two subjects died shortly after
initial evaluation and also were excluded. Four
patients could not perform the 6MWT on room
air (resting SpO2o88%) and were excluded.
Hence the final cohort included 81 patients. Of
these, there were 48 survivors and 33 non-
survivors. The 12-month mortality rate was 40.7%.
The mean time from initial referral to death was
227754 days in non-survivors. No subjects were
lost to follow-up.
Table 1 shows the demographic composition of
the cohort. Neither age nor gender distribution
differed between survivors and non-survivors.
Spirometric measures (Table 1) also failed to
segregate survivors from non-survivors. For exam-
ple, the mean TLC was 64.7715.2% predicted in
survivors compared to 66.6716.5% predicted in
those who died (P ¼ 0:34). The DLCO was similarly
reduced in both groups and did not correlate with
12-month survival (41.9710.8% predicted in survi-
vors versus 39.4712.6% predicted in non-survivors,
P ¼ 0:22).
Resting SpO2 on room air was significantly lower
in non-survivors (97.471.2% versus 94.272.6%,
P ¼ 0:007). Although desaturation during the
6MWT was common in all patients with IPF, non-
survivors had more pronounced declines in the SpO2
(mean fall 7.972.8% in survivors versus 10.573.3%
in non-survivors, P ¼ 0:002). Individuals living
greater than 12 months after initial evaluation
were also able to walk substantially farther than
ARTICLE IN PRESS
Table 1 Baseline patient variables.
Survivors (N ¼ 48) Non-Survivors (N ¼ 33) P
Age (years) 59.477.3 58.278.7 0.31
% Male 77.1 69.7 0.46
Supplemental oxygen requirement (%) 22.9 60.6 o0.001
FEV1 (% predicted) 63.5714.4 62.0714.0 0.35
TLC (% predicted) 64.7715.2 66.6716.5 0.34
DLCO (% predicted) 41.9710.8 39.4712.6 0.22
Resting SpO2 on room air (%) 97.471.2 94.272.6 0.007
Lowest SpO2 on 6MWT (%) 89.473.0 83.773.3 o0.001
Desaturation during 6MWT (%) 7.972.8 10.573.3 0.002
Distance walked on 6MWT (m) 406.9771.6 181.3795.2 0.005
DSP (m%) 364.8767.2 153.5781.5 o0.001
Abbreviations: DLCO—diffusion capacity for carbon monoxide; DSP—distance saturation product; FEV1—forced expiratory
volume in 1 s; FVC—forced vital capacity; SpO2—oxygen saturation by pulse oximetry; TLC—total lung capacity; 6MWT—six-
minute walk test.
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Figure 1 Distance saturation product.
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Figure 2 Receiver operator curves for 12-month survival.
Distance-saturation product in IPF 1737those dying during the observation period. More
specifically, survivors were able to walk more than
twice as far as non-survivors (Table 1).
The DSP correlated significantly with outcomes,
reflecting the cumulative contributions of its
component parts. The mean DSP was only
153.5781.5m% among non-survivors compared to
364.8767.2m% among survivors (Po0:001). Fig. 1
shows the distribution of DSPs among the cohort.
No patient who died during the subsequent 12
months achieved a DSP above 370m% and only
12.1% of deaths occurred in persons with
DSPs4300m%. In comparison, only 6.2% of survi-
vors had a DSPo200m%. The calculated AUC for
the DSP was 0.92 (Fig. 2) which was higher than the
AUC for the other variables analyzed, including the
individual components of the 6MWT (see Table 2).
The AUCs for both the SpO2 at rest and the lowest
SpO2 measured during the 6MWT each were 0.81and were statistically lower than the AUC for the
DSP (P ¼ 0:035 for both versus DSP). The AUC for
distance walked versus the DSP was also statisti-
cally different (P ¼ 0:040).
Through serial analysis of various DSP breakpoints
(e.g.,o200, 300m%, etc.), we noted that a thresh-
old value of 200m% segregated survivors from
non-survivors most accurately. Only 21.2% of non-
survivors achieved a DSP4200m%, compared to
93.7% of survivors. In other words, individuals with
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(95% confidence interval: 3.1–12.7). Fig. 3 shows
the Kaplan–Meier survival curve for the DSP. MeanTable 2 Area under the curve (AUC) for various
screening tests for 12-month mortality.
Parameter AUC
DSP 0.92
Distance 0.89
SpO2 at rest 0.81
SpO2 nadir 0.81
DesaturationX4% 0.33
DLCO 0.58
FVC 0.53
FEV1 0.52
TLC 0.48
The AUC measures the area under the receiver operating
curve. Larger AUCs suggest improved accuracy for a
screening test.
Abbreviations: DLCO—diffusion capacity for carbon mon-
oxide; DSP—distance saturation product; FEV1—forced
expiratory volume in 1 s; FVC—forced vital capacity;
SpO2—oxygen saturation by pulse oximetry; TLC—total
lung capacity.
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Figure 3 DSPp200m% as a predictor of 12-month
survival.
Table 3 Screening characteristics of various parameter
Sensitivity (%) Specificity (%) Pos
val
DSPp200 78.8 91.7 86.
Distance
walkedp300m
78.8 87.5 81.
Lowest SpO2p88% 81.8 56.3 56.
FVC 60–79%
predicted
39.4 62.5 41.
Abbreviations: DSP—distance saturation product; FVC—forced visurvival times were 18.0% longer among patients
able to achieve a DSP4200m% compared to those
who could not (Po0:001).
As a screening tool for 12-month mortality, the
DSP had excellent performance characteristics. As
demonstrated in Table 3, the sensitivity, specificity,
positive predictive value and negative predictive
value for a DSP of o200m% were 78.8%, 91.7%,
86.7%, and 86.3%, respectively. A DSP breakpoint of
200m% correctly identified 26 of 33 deaths and
250m% correctly identified all but two deaths. The
breakpoint for distance walked with the best
predictive accuracy was 300m. Although compar-
able, distance walked demonstrated slightly less
overall accuracy than the DSP. Desaturation to less
than 88% during the 6MWT had slightly better
sensitivity than the DSP but was less specific
(Table 3). The DSP appropriately identified more
patient outcomes compared to the individual 6MWT
parameters. For example, the DSP correctly cate-
gorized three additional patient outcomes which
would have been misclassified by distance walked
and eight which would have been misclassified by
desaturation. Each of these parameters proved
more accurate in predicting outcomes than static
measures of lung function such as the FVC and the
DLCO (Table 3).Discussion
IPF is associated with high mortality rates and may
be preceded by a progressive decrease in exercise
capacity. Few routinely obtained measured vari-
ables, especially spirometric values, accurately
predict mortality or reflect the functional limita-
tions associated with this disease. However, mea-
surements of this functional limitation (decreased
exercise capacity) have been shown to be pre-
dictive of subsequent outcomes.
The 6MWT represents a standardized, easy to
perform, reproducible means to measure func-
tional capacity and has been shown to be a usefulfor mortality in IPF.
itive predictive
ue (%)
Negative predictive
value (%)
Accuracy
(%)
7 86.3 86.8
3 85.7 83.9
3 81.8 66.6
9 60.0 53.1
tal capacity.
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walked and desaturation during the 6MWTcorrelate
with mortality.18–20 However, it is unclear whether
distance or the SpO2 nadir provides more accurate
prognostic information. The distance walked during
the 6MWT has been shown to have less variability
than the SpO2 in patients with IPF.
18 Conversely, in
a study by Lama et al.19 desaturation provided
better prognostic information than distance. These
discordant findings may reflect that distance
walked is highly dependent on patient effort.
Similarly, limited efforts leading to a truncated
distance and/or time walked may prevent the
subsequent development of hypoxia. In turn, the
development of hypoxia may result in dyspnea and
prevent further distance walked. The combination
of these two parameters may be less dependent on
patient effort or the potential variability of either
individual constituent. Therefore, a composite
index could prove more reproducible and hence
more reliable as a predictor of outcomes.
In a cohort of patients with IPF, we demonstrate
that both distance walked and the SpO2 nadir are
both independently predictive of outcomes. Com-
bining both of these parameters into a composite
index, the DSP provided slightly more accurate
prognostic information than either of its compo-
nent parts. Like other composites, this index is less
reliant on any single component and may be more
reliable. Formal determination of the reliability of
the DSP is therefore required. Our purpose in this
initial pilot study was to develop the concept of the
DSP.
The DSP achieved the greatest AUC as a predictor
of mortality and correctly identified outcomes
better (predicted survival or subsequent death in
more patients) than if either parameter was used
independently. This highlights how the DSP may
enhance the resolution of the 6MWT. The most
accurate DSP breakpoint (p200m%) was slightly
more predictive of mortality than the most accu-
rate distance walked breakpoint (p 300m) or SpO2
breakpoint (p88%).
Since IPF represents a complex, progressive
disease which is nearly always fatal, physicians
face difficult decisions after confirming this diag-
nosis. Not only must they counsel patients about
end of life issues but they must determine if and
when to refer a patient for lung transplantation.
They must also decide about treatment options and
enrollment in clinical trials. Hence, having a simple
tool for outcome prediction in IPF is crucial.
Multiple different parameters have been exam-
ined for their predictive ability in IPF. Prior
research reveals that age, presence of clubbing
and serial changes in PFT values correlate withsurvival.3,5,7,8,10,15 Each of these variables has the
advantage of being easily measurable. However,
their discriminatory power is limited. For example,
Erbes and co-workers studied a cohort of 99
patients and found that although the FVC and TLC
correlated with survival, the correlation was
weak.10 A recent prospective trial of patients with
IPF performed by King et al.27 found that mortality
was equivalent across a wide range of FVC values.
Other factors previously shown to relate to
mortality include certain biomarkers, findings
on CT scan, the results of surgical lung biopsy,
and integrative severity of illness scoring
tools.1–7,9–16,27–30 The histopathologic degree and
extent of fibroblast foci findings from surgical lung
biopsy are associated with subsequent mortal-
ity.3,11,12,15,30 For each one grade increase in the
amount of fibrosis, King et al.3 observed that the
risk for death approximately doubled. Unlike the
6MWT, lung biopsy is necessarily more invasive and
pathologic interpretation of biopsy specimens may
be prone to inter-observer variability.31,32 The
clinical, radiological and physiological (CRP) scor-
ing system represents an attempt to improve
outcome predictions in IPF by integrating informa-
tion from different aspects of the evaluation for
IPF.2,3 Although the CRP provides good resolution
and has been validated at several institutions, it is
cumbersome to calculate. Additionally, the CRP
necessitates that the patient undergo CPET in order
to determine arterial oxygenation at maximal
exercise. Information from patient registries in-
dicates that CPET is infrequently performed in
clinical practice and may have poor reproducibility
in patients with fibrotic lung diseases.18
Multiple investigators have documented the
relationship between the 6MWT and mortality in
chronic pulmonary diseases. For a variety of
diseases, ranging from cystic fibrosis to idiopathic
pulmonary arterial hypertension, the 6MWTappears
effective at discriminating survivors from non-
survivors.17–20,22 Because of this, the 6MWT has
been used as an endpoint in a number of clinical
trials for these conditions and has been integrated
into algorithms for choosing when to refer such
individuals for transplantation. Intuitively, the
6MWT should correlate with survival since it
represents a dynamic test that integrates overall
exercise tolerance. As such, performance on the
6MWT may be affected not only by the underlying
disease but also by chronic co-morbid conditions
and factors which complicate the primary condition
(for example, pulmonary hypertension). The 6MWT
has also been shown to correlate with both oxygen
uptake and peak exercise oxygenation during a
CPET.17,18 Eaton et al.18 recently found that the
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was excellent and correlated to the maximum
oxygen uptake during CPET. Therefore, the 6MWT
provides information about the patient’s health and
physiologic status that approximates the insights
gleaned from the more expensive and time con-
suming ‘‘gold-standard’’ for physiologic testing.
More recently, Hallstrand and associates have
shown that a number of parameters from a timed
walk test correlate independently with survival.20
Our results build on this earlier work by both
confirming the value of the 6MWT and by develop-
ing a means for maximizing the prognostic informa-
tion obtained during the test. By ROC analysis, it
appears that a DSP breakpoint of 200m% has the
greatest discriminatory power with regards to
mortality. This index may provide important in-
formation which could impact decisions pertaining
to potential therapies and need for transplanta-
tion, as well as provide more accurate counseling
regarding prognosis.
Our study has several limitations. First, we
included only 6MWTs performed on room air. This
may have limited the performance of patients
requiring supplemental oxygen. Given that the
need for supplemental oxygen is common among
patients with advanced IPF, including subjects in
this cohort, this exclusion may appear to limit the
applicability of our results. However, this was
necessary to provide more homogenous data to
facilitate this initial analysis and to limit confound-
ing. Additionally, only 4% of subjects in our cohort
were eliminated from analysis due to resting
hypoxia. Therefore our standard of testing may be
more applicable to the majority of patients with
IPF. In addition, previous studies of the 6MWT have
also excluded individuals using supplemental oxy-
gen.19 Second, the 6MWT may be influenced by
patient effort which could alter the total distance
walked and subsequent desaturation. This is a
limitation of the 6MWT and all exercise testing
and is not unique to the DSP. Third, we did not
control for multiple additional factors which may
influence survival, such as smoking history, age, co-
morbid conditions, HRCT appearance and results
from lung biopsy in analyzing our DSP index. We
specifically opted not to control for these impor-
tant co-variants in order to keep our new measure
as simple as possible and applicable to a variety of
clinical settings (e.g. academic medical center
versus community-based provider). A larger sample
size would be required to allow statistical compar-
isons including all of these variables. Our sample
size precluded this approach but was, none the
less, as large or larger than previous studies using
the 6MWT in patients with IPF. Fourth, the 6MWTsevaluated were performed at the time of referral
and not necessarily at the time of diagnosis which
may create a form of lead-time bias. This fairly
broad range of duration and severity of disease
though, likely reflects that seen by most clinicians
and may reflect the spectrum of DSP measures seen
in this study. Future studies should evaluate serial
6MWTs over the course of the disease to determine
if it reflects the progressive functional limitation
seen with this disease and can be validated as a tool
to predict the risk and timing of mortality. Finally,
our study was retrospective. Nevertheless, our
endpoint, mortality, is not subject to ascertain-
ment bias. The use of this index as a simple tool to
predict outcomes in IPF must ideally be validated in
the context of a prospective study.
In conclusion, the DSP represents a new measure
for predicting survival in IPF. Patients with DSPs
below 200m% are at a significantly increased risk of
death in the ensuring 12 months. The simplicity,
ease of calculation and availability of the 6MWT in a
variety of clinical settings underscore the potential
utility for the DSP as a tool in the evaluation of
patients with IPF.Acknowledgments
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